BMY

Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.

AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretched.

Pfizer beats third-quarter earnings and revenue estimates, driven by strong non-COVID product sales, and increases its 2026 guidance.

For questions about this article or underlying research, email help@trefis.com.

Tempus AI reported Q3 2026 revenue of US$411.54 million and a net loss of US$14.85 million, with management raising full-year revenue guidance to a range of US$1.60 billion to US$1.605 billion and signing multi-year data agreements with Bristol Myers Squibb and Pathos AI. The new collaborations give Tempus AI multi-year visibility on data and applications income, and the narrower loss suggests ope

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 6.9% year on year to $13.07 billion. The company expects the full year’s revenue to be around $50 billion, close to analysts’ estimates. Its non-GAAP profit of $1.35 per share was 12.4% above analysts’ consensus estimates.

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Bristol Myers Squibb’s third quarter results reflected robust growth in its core portfolio, led by strong commercial execution and momentum across newer products. Management pointed to double-digit sales gains in key brands such as Reblozyl, Breyanzi, and Camzyos, as well as successful launches of new therapies like Symvexis. CEO Christopher Boerner emphasized the company’s success in advancing it